ANTI-NMDA RECEPTOR ENCEPHALITIS · LGI1 · CASPR2 · AUTOIMMUNE LIMBIC ENCEPHALITIS
A physician-led, laboratory-verified treatment programme designed as an adjunct to standard immunotherapy — targeting antibody-mediated neuronal damage, neuroinflammation and synaptic dysfunction to support cognitive recovery, seizure reduction and functional rehabilitation in autoimmune encephalitis patients.
Request Medical ConsultationAbout the Condition
Autoimmune encephalitis (AE) is a group of inflammatory brain diseases caused by the immune system producing antibodies that attack neuronal surface proteins, synaptic receptors or intracellular antigens. Unlike infectious encephalitis, the damage is driven by the patient's own immune system — often with no external pathogen involved.
Symptoms develop over days to weeks and may include seizures, memory loss, psychiatric disturbance (psychosis, agitation, personality change), movement disorders, speech dysfunction and reduced consciousness. In severe cases — particularly anti-NMDA receptor encephalitis — patients may require intensive care.
Autoimmune encephalitis is increasingly recognised as a treatable cause of encephalitis, with early aggressive immunotherapy associated with better outcomes. However, a significant proportion of patients experience incomplete recovery, relapses or persistent cognitive deficits despite standard treatment — which is where adjunctive cellular therapy offers a meaningful additional dimension.
Anti-NMDA Receptor Encephalitis
The most common and well-characterised form. Predominantly affects young women, often associated with ovarian teratoma. Presents with psychiatric symptoms, seizures, movement disorders, autonomic instability and reduced consciousness. Antibodies target the GluN1 subunit of the NMDA receptor, disrupting synaptic transmission.
Anti-LGI1 Encephalitis
Typically affects older adults (median age 60+). Characterised by faciobrachial dystonic seizures, cognitive decline and hyponatraemia. Antibodies target leucine-rich glioma-inactivated 1 protein at the synapse. Generally responds well to immunotherapy but cognitive sequelae are common.
Anti-CASPR2 Encephalitis
Associated with limbic encephalitis, neuromyotonia and Morvan syndrome. Antibodies target contactin-associated protein-like 2, disrupting potassium channel function. May present with peripheral nerve hyperexcitability alongside central symptoms. More common in men over 50.
Seronegative Autoimmune Encephalitis
Clinical presentation consistent with autoimmune encephalitis but without identifiable antibodies using current commercial assays. Diagnosis is based on clinical criteria, MRI findings, CSF pleocytosis and exclusion of alternative causes. Represents a diagnostic and therapeutic challenge — treatment response may be less predictable.
Our program is individually adapted for all subtypes and all stages of progression.
Important: Each patient is accepted into the programme only after a comprehensive individual medical assessment, which evaluates antibody subtype, disease severity, current immunotherapy regimen and overall clinical profile.
We do not replace standard immunotherapy for autoimmune encephalitis. Our programme is designed to complement established treatment — targeting residual neuroinflammation, synaptic repair and cognitive rehabilitation at the cellular level.
Clinical Outcomes
The following data are derived from structured observational analysis of patients treated at BioCells Medical between 2018 and 2025. All figures represent aggregated clinical registry outcomes with longitudinal follow-up. These are observational results — not randomised controlled trial data — and do not constitute a guarantee of therapeutic effect.
26
autoimmune encephalitis patients treated
72%
demonstrated measurable cognitive or functional improvement within 2–4 months
65%
showed reduction in seizure frequency or severity
58%
experienced clinically observable improvement in psychiatric symptoms
−0.8 pts
average mRS score change in the first 4 months
69%
maintained sustained cognitive gains — follow-up to 2 years
Improved short-term memory and recall
68%
Reduced seizure frequency or transition to seizure-free status
61%
Normalisation of personality and behavioural patterns
55%
Improved executive function and concentration
63%
Reduction in psychiatric symptoms (anxiety, agitation, psychosis)
52%
2–6 weeks
Initial neurological response
2–4 months
Clinically meaningful change
6–12 months under continued monitoring
Continued cognitive and functional improvement
Important: Outcomes depend on antibody subtype, disease severity at baseline, duration of illness before treatment, response to prior immunotherapy and individual biological factors. Anti-NMDA receptor encephalitis patients with early treatment initiation tend to show the strongest response. Individual results may vary significantly.
Find out if our program can help in your specific case. The initial medical consultation is free and carries no obligation.
Request ConsultationPatient Stories
“Our daughter could not remember our names half the time. Standard immunotherapy stabilised her, but the memory gaps remained. After starting the programme in Warsaw, she began retaining conversations again. She is back at university now, part-time, but she is there. Watching her pack her bag for class was the first time I cried from relief, not fear.”
Patient's mother
Anti-NMDA receptor encephalitis · USA
Every case is assessed individually by our physician team. Request a consultation to discuss your specific situation with our physician team.
Request ConsultationThe BioCells Program
Our autoimmune encephalitis programme combines five biological components into a single personalised protocol, administered as an adjunct to the patient's existing immunotherapy. No two protocols are identical — each is constructed following a detailed medical evaluation of the patient's antibody profile, disease stage and clinical priorities.
No surgery required
Treatment is delivered by intravenous infusion or targeted local injection using specialised medical systems — not surgical instruments.
No general anaesthesia
Important for autoimmune encephalitis patients who may have autonomic instability or ongoing seizure management requirements.
No risk of immune rejection — autologous option
Where clinically appropriate, we use the patient's own cells. Zero risk of graft-versus-host disease with autologous protocols.
Targets residual damage, not just the acute attack
Standard immunotherapy controls the immune attack. Our protocol targets what remains after — synaptic repair, hippocampal recovery, BBB restoration and persistent neuroinflammation.
Complements existing immunotherapy
Our programme is designed to work alongside rituximab, IVIG, plasma exchange and other standard immunosuppressive regimens. Patients do not need to discontinue existing treatment.
Treatment at your location worldwide
Our medical team is available to conduct treatment at our Warsaw clinic or to travel to the patient's location anywhere in the world. For patients with severe encephalitis where travel is medically inadvisable, this removes a critical barrier to accessing care.
What It Is
MSCs are multipotent regenerative cells with proven immunomodulatory and neuroprotective properties. In autoimmune encephalitis, their capacity to modulate aberrant immune responses and support neuronal repair makes them particularly relevant.
How It Is Done
Cells are collected from the patient's own bone marrow (autologous, approximately 50 ml under local anaesthesia) or sourced from a certified donor (allogeneic), depending on individual clinical indications. All cells are then expanded, quality-controlled and tested in our certified Warsaw laboratory before administration.
Biological Mechanisms
How This Helps in Autoimmune Encephalitis
In autoimmune encephalitis, pathogenic antibodies cross the disrupted blood-brain barrier and directly attack neuronal receptors. MSCs address multiple levels of this process — suppressing the immune cells that produce these antibodies, reducing inflammatory damage to brain tissue, and supporting BBB integrity to limit further antibody infiltration into the CNS.
Your Medical Board
The exact combination, dosage, sequencing and delivery method of all five components is determined individually by our medical board for each patient, in coordination with their existing immunotherapy regimen. No two treatment protocols are identical. Your programme is constructed based on your specific antibody subtype, disease severity, current medications and clinical priorities.
Your protocol is designed individually. Speak with our medical team to understand what your personalised program would include.
Request ConsultationPatient Journey
Your case is reviewed remotely by our physician team. We assess your diagnosis, antibody subtype, current immunotherapy regimen, mRS/CASE scores and treatment goals. This consultation is free and carries no obligation.
A detailed review of all medical documentation including antibody panels, MRI findings, EEG data and neuropsychological assessments. Our medical board evaluates eligibility, confirms safety parameters and designs your personalised therapeutic protocol.
Your cells are collected, isolated, expanded and quality-tested in our certified Warsaw laboratory. Each batch receives a full traceability certificate. This stage typically takes 2–3 weeks.
Cells are delivered by intravenous infusion or targeted local administration — no surgery, no general anaesthesia. Treatment is available at our Warsaw clinic or with our medical team at your location worldwide. Airport transfers, accommodation and visa support are included in the programme. Where clinically appropriate, our medical board may approve a travelling treatment programme — our medical team flies directly to the patient.
Structured cognitive rehabilitation sessions with our specialist, adapted to your current neurological status and cognitive profile. Includes memory training, executive function exercises and psychiatric support. Available at our clinic or remotely coordinated with your local medical team.
Your dedicated coordinator monitors cognitive function, seizure status, psychiatric symptoms and overall recovery trajectory. A medical-grade wearable bracelet supports continuous health tracking regardless of your location.
The first step is free. Request a medical consultation and our medical consultant will contact you within 24 hours.
Request ConsultationSafety Profile
Cellular therapy is considered safe when delivered under proper medical supervision and according to validated protocols. In our practice, the procedure is well-tolerated by the majority of autoimmune encephalitis patients.
Temporary mild reactions — such as transient local discomfort at the infusion site, slight fatigue or low-grade temperature — may occur in a minority of patients. These are typically short-lived and indicate active immune engagement.
A final medical assessment is performed on-site before every treatment session. If a patient's status has changed — including seizure activity or psychiatric deterioration — the programme may be temporarily modified or postponed for safety reasons.
All contraindications are evaluated individually. A contraindication in one clinical context does not necessarily preclude treatment in a different context — this is always determined by physician assessment. Coordination with the patient's immunotherapy team is maintained throughout.
Standard Contraindications
Active acute infection or fever
Active malignancy or ongoing chemotherapy / radiotherapy
Severe decompensated cardiac or renal failure
Pregnancy
Post-Treatment
Dedicated neurological rehabilitation specialist
monitors cognitive function, seizure status and psychiatric recovery
Personalised cognitive rehabilitation programme
memory training, executive function exercises, language recovery protocols
Medical-grade wearable monitoring
continuous physiological data collection supporting clinical decision-making
Long-term coordinator support
proactive check-ins, clinical guidance and response to any changes in neurological status
Continued clinical access
our medical team remains available for ongoing reassessment and protocol adjustment
Neuronal recovery in autoimmune encephalitis follows its own trajectory. Cognitive and psychiatric improvement may continue for months after the acute treatment phase. Structured follow-up ensures that emerging gains are captured, rehabilitation is adjusted accordingly, and any signs of relapse are identified early.
Get Started
If you or someone you love has been diagnosed with autoimmune encephalitis, our medical team is available for a free, no-obligation medical consultation — based on your diagnosis, antibody subtype, current treatment and individual clinical profile.
We review every inquiry personally. You will speak with a physician, not an administrator.
Submit your case online or by phone
Our medical consultant contacts you to review your documents
The medical board presents your personalised treatment plan
Request a Consultation
Tell us about your condition. Our medical consultant will contact you within 24 hours to review your documents.
Open Consultation FormMultilingual coordination — English, Italian, French, Russian, Polish
Evidence Base
Our clinical approach is informed by and consistent with published research in the field of regenerative medicine.
